Stock News

The deepest extension hole reached 907.4 metres downhole; TomaGold will use geophysical surveys to select further drill targets.

Atlas showed 13.9 per cent complete clearance on the rival pill at week 16 as Takeda awaits an FDA action in early 2027.

The ASX explorer plans to map the Manna Hill and Waukaringa goldfields after licence grant and begin drilling in early 2027.

The Western Australian deposit also holds a 12.5-million-tonne iron resource; a study of potential economics is due in December.

A 350-patient Phase 3 study is testing PSMA PET with MRI before biopsy; Telix's Sept. 30 release gives no readout or NDA submission date.

Battle Green can require a share-funded note purchase, while Vireo can trigger one at a lower share price; the maturity route uses a future trading average.

Customer commitments cover more than 70 per cent of A201's 21.7-megawatt capacity before planned energization in early 2027.

A 37.1-minute placebo-adjusted shift in sleep onset supports Vanda's plan to seek a third U.S. HETLIOZ indication.

DBV requested priority review for VIASKIN Peanut after reporting a 31.8-point responder advantage over placebo in VITESSE.

The miner expects about 102.2 million shares outstanding after receipt conversion and aims to close the Nevada acquisition around Oct. 6.

IMC Holdings retains liabilities under a C$9.4M cap subject to mutual adjustment; direct subsidiary debts are excluded from that cap.

The package includes 12 months of stability data from a new manufacturer after two manufacturing-related FDA letters.

Final Nakalakwana assays accompany a 291-square-kilometre gravity survey over the Thole-Copper Snake anomaly in Botswana.

Exascale reported US$2.7M cash at June 30 and said its Aug. 27 merger gave it access to about US$11.8M in net cash proceeds.

ECG-MR is cleared to flag possible valve disease in at-risk patients 65 and older, while Tempus's Sept. 28 release gave no rollout date.

The preliminary proxy advances the proposed quantum-security deal toward a shareholder vote, with closing still targeted for the fourth quarter.

HUTCHMED says the application covers MET-driven lung cancer after EGFR inhibitor treatment, supported by a 338-patient Phase 3 trial.

The proposed subscription would leave Goldgroup with about US$91 million in cash before costs and other commitments.

Plurilock holders would receive C$0.084 in cash and 0.0763 QeM shares for each share if the arrangement closes.

First U.S. approval covers peripheral thyrotoxicosis in MCT8 deficiency; Egetis expects commercial availability eight to 10 weeks after Sept. 28.

CEO Matt Cole says SATA supplied 85 per cent of capital raised; cash stood at US$248.8 million on Sept. 25.

The Llama infill result comes as mobile crushing helps keep the Nunavut mine on course for 170,000 to 200,000 ounces in 2026.

A strategic investor exercised a participation right as the company's two September financings issued 13.1 million new shares.

A signed trial pact covers ivonescimab and sonesitatug vedotin in gastrointestinal cancers; Summit expects the share sale to close by Oct. 2.

The Sept. 29 announcement assigns the other US$500M to five Samsung affiliates but does not break down their commitments or name a Helix project.

The cannabis banking platform expects SHFS to keep its Nasdaq ticker and round fractional holdings up when split-adjusted trading begins Sept. 30.

The closed SPR2015 deal carries a US$400M upfront payment; further value depends on development and commercial milestones.

The three-year ceiling includes options; DLH did not disclose the funded base period or update its US$408.5M June 30 backlog.

The Sept. 25 adult Parkinson's approval clears one condition for a payment-rights purchase expected to close Sept. 29.

The 18-month HHS award covers all three Xacta modules plus integration, training and migration services.

The perpetual, royalty-free agreement covers two brands, while a Texas launch still requires final state licensure and regulatory approval.

Blöte starts Oct. 1 as Canopy seeks German medical cannabis growth; its June quarter international cannabis revenue was C$9.6M.

The Sept. 25 charter amendment doubles common-share capacity and raises the cannabis landlord’s preferred-share ceiling without a shareholder vote.

Its Texas subsidiary would pay PsyLabs the milestones for the first drug candidate; the binding terms lapse without a definitive agreement by Nov. 30.

The Sept. 28 vote approved articles changes, preferred allotments and market repurchases; a possible IPO still needs an FCA-approved prospectus.

The four-year line starts at SOFR plus 175 basis points and can back utility and equipment obligations with letters of credit.

The 40-patient tipelukast study missed its week-24 liver-fat and triglyceride comparisons, although secondary HDL measures improved.

The Manitoba reserve plan adds two years to Snow Lake's schedule and forecasts 185,000 gold ounces a year on average through 2030.

Under current budgets, Fulcrum expects a £2.5M loan draw and £500K equity subscription to fund its pilot and first Teck-Hughes programme.

The AIM software group ended a process begun in March and reported £6.3 million revenue for the six months to July 31.